A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

Phase 2 Completed 421 enrolled XenoPort, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)

Timeline

Start: 2008-03
Primary completion: 2009-02
Completion: 2009-02

Publications

Rauck R, Makumi CW, Schwartz S, Graff O, Meno-Tetang G, Bell CF, Kavanagh ST, McClung CL. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013 Jul;13(6):485-96. doi: 10.1111/papr.12014. Epub 2012 Nov 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pregabalin	Small molecule	300 mg	Oral
Subject	gabapentin enacarbil	Small molecule	1200 mg	Oral
Subject	gabapentin enacarbil	Small molecule	2400 mg	Oral
Subject	gabapentin enacarbil	Small molecule	3600 mg	Oral

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

Summary

Timeline

Publications

Drugs

Indications